SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 31.22-0.4%Dec 31 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gene Weisskopf who wrote (229)7/31/1998 8:04:00 AM
From: Harold Engstrom   of 340
 
The article you posted didn't seem negative to me. Copaxone is doing much better than I ever thought it would, and now has close to 20% market share - probably more than 15,000 patients. That is OK, really, especially with the MS market expanding the way it is.

And Teva doesn't need to hit home runs to win - just hit singles and doubles consistently. To expect a company to come out with a "Viagra" is rather a high bar to set. I think part of the problem with Teva's press in Israel is that they are the only game in town and everyone will have an opinion.

That is not to say that Teva doesn't still have some hurdles and not to say that past criticism of management is not warranted.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News